BioSpace News Archive

SimBioSys and Magic Leap join forces to integrate AI-powered TumorSight Viz with AR technology, revolutionizing surgical precision and patient outcomes in cancer care.

Tris Pharma, Inc. has entered into a licensing agreement with Braingaze Ltd. and launched its new business, Tris Digital Health, which will focus on the development and commercialization of digital diagnostic and therapeutic products for neurological health conditions.

Jaguar Health, Inc. today announced that it has signed an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group PLC.

Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company” or “Inspira”), a breakthrough medical technology company, is proud to announce the signing of a collaboration term sheet (the “Term Sheet”) with the Beilinson Hospital in Israel for the evaluation of its proprietary INSPIRA ART100 device (the “Device”) in organ transplant procedures.

QT Imaging Holdings, Inc. is proud to announce positive data regarding the diagnostic performance of QTI’s Breast Acoustic CT TM Scans for mass detection from its second blinded multi-reader multi-case study.

NMDP BioTherapies ℠, formerly Be The Match BioTherapies unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings.

BioArctic AB hereby announces that the Nomination Committee for BioArctic AB presents the following proposals regarding the resolution on the number of board members and the election of board members and Chairperson of the Board at the Annual General Meeting on May 22, 2024.

SPARK Neuro, a leader in brain health diagnostics, announces the appointment of Dr. Richard J. Caselli as its Medical Director.

Mabwell presented the preclinical research findings of three potential novel drug candidates in poster format at the American Association for Cancer Research (AACR) Annual Meeting, held from April 5 to 10, 2024.

According to Nova One Advisor, the global diagnostic testing market is valued at USD 211.27 billion in 2023